Skip to navigation menu Skip to content
Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept (Orencia) in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (LIMIT-JIA)

LIMIT JIA

What is the goal of the study?

The study objective is to evaluate the effectiveness of a 24-week course of treatment with a T-cell co-stimulation inhibitor (abatacept (Orencia)) plus usual care versus usual care to prevent polyarthritis (5 or more joints), uveitis, or treatment with other systemic medication(s) for JIA (e.g one or more of the following: glucocorticoids, DMARD or biologic) medication within 18 months of randomization in children with recent-onset limited JIA.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: